805
Views
7
CrossRef citations to date
0
Altmetric
Research Articles

Determining similarities of COVID-19 – lung cancer drugs and affinity binding mode analysis by graph neural network-based GEFA method

, &
Pages 659-671 | Received 01 Jun 2021, Accepted 21 Nov 2021, Published online: 08 Dec 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Muthu Kumar Thirunavukkarasu, Shanthi Veerappapillai & Ramanathan Karuppasamy. (2023) Sequential virtual screening collaborated with machine-learning strategies for the discovery of precise medicine against non-small cell lung cancer. Journal of Biomolecular Structure and Dynamics 0:0, pages 1-14.
Read now

Articles from other publishers (5)

Huanan Rao, Xiaominting Song, Jieting Lei, Peng Lu, Guiying Zhao, Xin Kang, Duanna Zhang, Tingrui Zhang, Yali Ren, Cheng Peng, Yuzhi Li, Jin Pei & Zhixing Cao. (2022) Ibrutinib Prevents Acute Lung Injury via Multi-Targeting BTK, FLT3 and EGFR in Mice. International Journal of Molecular Sciences 23:21, pages 13478.
Crossref
Yaowen Gu, Si Zheng, Qijin Yin, Rui Jiang & Jiao Li. (2022) REDDA: Integrating multiple biological relations to heterogeneous graph neural network for drug-disease association prediction. Computers in Biology and Medicine 150, pages 106127.
Crossref
Imra Aqeel, Muhammad Bilal, Abdul Majid & Tuba Majid. (2022) Hybrid Approach to Identifying Druglikeness Leading Compounds against COVID-19 3CL Protease. Pharmaceuticals 15:11, pages 1333.
Crossref
Cafer Budak & Vasfiye Mençik. (2022) Detection of ring cell cancer in histopathological images with region of interest determined by SLIC superpixels method. Neural Computing and Applications 34:16, pages 13499-13512.
Crossref
Rajashri R. Naik, Ashok K. Shakya, Safwan M. Aladwan & Mohamed El-Tanani. (2022) Kinase Inhibitors as Potential Therapeutic Agents in the Treatment of COVID-19. Frontiers in Pharmacology 13.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.